Sugi Predict

Sugi Predict / Compounds / SCHEMBL519915

SCHEMBL519915

SCHEMBL519915

O=S(=O)(c1cccc(B(O)O)c1)N1CCCC1

nearest known ligand 0.69

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 7/20 0.65
▸ SMN1; SMN2 Q16637 2/20 0.65
▸ LMNA P02545 3/20 0.62
▸ TSHR P16473 3/20 0.62
▸ HTT P42858 1/20 0.62
▸ MEN1 O00255 3/20 0.61
▸ KMT2A Q03164 3/20 0.61
▸ MAPT P10636 1/20 0.60
▸ IL1RN P18510 1/20 0.60
▸ NPSR1 Q6W5P4 3/20 0.59
▸ THRB P10828 1/20 0.59
▸ GAA P10253 2/20 0.57
▸ USP2 O75604 1/20 0.52
▸ MCOLN3 Q8TDD5 2/20 0.51
▸ L3MBTL1 Q9Y468 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29956375 0.98 ALDH1A1 (0.63) ALDH1A1SMN1; SMN2LMNATSHRHTT
SCHEMBL3915596 0.98 ALDH1A1 (0.63) ALDH1A1SMN1; SMN2LMNATSHRHTT
SCHEMBL12538126 0.86 TSHR (0.60) ALDH1A1SMN1; SMN2LMNATSHRHTT
SCHEMBL21813105 0.86 POLB (0.61) SMN1; SMN2LMNATSHRHTTKMT2A
SCHEMBL29664081 0.86 TSHR (0.60) ALDH1A1SMN1; SMN2LMNATSHRHTT
SCHEMBL959386 0.81 USP2 (0.68) ALDH1A1SMN1; SMN2LMNATSHRHTT
SCHEMBL14489550 0.79 ALDH1A1 (0.69) ALDH1A1SMN1; SMN2LMNATSHRHTT
SCHEMBL12674480 0.79 ALDH1A1 (0.74) ALDH1A1SMN1; SMN2LMNATSHRHTT
SCHEMBL1742543 0.79 USP2 (0.71) ALDH1A1SMN1; SMN2LMNAHTTMEN1
SCHEMBL30989168 0.78 ALDH1A1 (0.58) ALDH1A1SMN1; SMN2LMNATSHRHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250066308-A1 BICYCLIC FUSED RING DERIVATIVE OR SALT THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING SAME YUHAN CORPORATION (KR) 2025-02-27 — — US disclosed
CN-114555588-B Quinazoline compounds as AXL inhibitors 南京正大天晴制药有限公司 2024-08-06 — — CN disclosed
CN-118339145-A Bicyclic fused ring derivatives or salts thereof and pharmaceutical compositions containing the same 柳韩洋行 2024-07-12 — — CN disclosed
EP-4397655-A1 BICYCLIC FUSED RING DERIVATIVE OR SALT THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING SAME Yuhan Corporation (KR) 2024-07-10 — — EP disclosed
CN-113840820-B Phthalazinone compounds and uses thereof ST制药株式会社 2024-05-03 — — CN disclosed
WO-2023055124-A1 BICYCLIC FUSED RING DERIVATIVE OR SALT THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING SAME 주식회사유한양행 2023-04-06 — — WO disclosed
US-20220340893-A1 BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES NUEVOLUTION A/S (DK) 2022-10-27 — — US disclosed
CN-114555588-A Quinazolines as AXL inhibitors 南京正大天晴制药有限公司 2022-05-27 — — CN disclosed
CN-113840820-A Phthalazinone compounds and uses thereof ST制药株式会社 2021-12-24 — — CN disclosed
WO-2020242245-A1 PHTHALAZINONE COMPOUNDS AND USE THEREOF 에스티팜 주식회사 2020-12-03 — — WO disclosed
WO-2012129491-A1 TRPV3 MODULATORS ABBOTT LABORATORIES (US) 2012-09-27 — — WO disclosed
US-20120028919-A1 PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS CEPHALON, INC. (US) 2012-02-02 — — US disclosed
EP-2376491-A1 PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS Cephalon, Inc. (US) 2011-10-19 — — EP disclosed
US-20110201581-A1 Novel Compounds 010 ASTRAZENECA AB (SE) 2011-08-18 — — US disclosed
US-7902181-B2 Compounds 010 ASTRAZENECA AB (SE) 2011-03-08 — — US disclosed
US-20100317657-A1 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES NOVARTIS AG 2010-12-16 — — US disclosed
EP-2231597-A1 PEPTIDYL NITRILES AND USE THEREOF AS DIPEPTIDYL PEPTIDASE I INHIBITORS AstraZeneca AB (SE) 2010-09-29 — — EP disclosed
WO-2010071885-A1 PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS CEPHALON, INC. (US) 2010-06-24 — — WO disclosed
US-20090306042-A1 Novel Compounds 010 ASTRAZENECA AB (SE) 2009-12-10 — — US disclosed
WO-2009074829-A1 PEPTIDYL NITRILES AND USE THEREOF AS DIPEPTIDYL PEPTIDASE I INHIBITORS ASTRAZENECA AB (SE) 2009-06-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250066308-A1 BICYCLIC FUSED RING DERIVATIVE OR SALT THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING SAME LOX, XDH, IL4I1 ALDH1A1 571/4885SMN1; SMN2 4312/4885LMNA 834/4885
US-20090306042-A1 Novel Compounds 010 MRGPRX2, F12, TBXA2R ALDH1A1 1620/4885SMN1; SMN2 1830/4885LMNA 2051/4885
US-20110201581-A1 Novel Compounds 010 MRGPRX2, F12, TBXA2R ALDH1A1 1620/4885SMN1; SMN2 1830/4885LMNA 2051/4885
US-20100317657-A1 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES PRKCA, CSNK1A1, ABL1 ALDH1A1 2405/4885SMN1; SMN2 2076/4885LMNA 860/4885
US-20120028919-A1 PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS JAK2, ALK, ABL1 ALDH1A1 779/4885SMN1; SMN2 4722/4885LMNA 3783/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.